Exploratory analysis of prognostic factors for lenvatinib in radioiodine‐refractory differentiated thyroid cancer. Issue 9 (23rd April 2019)

• Record Type: Journal Article
• Authors: Suzuki, Chiaki; Kiyota, Naomi; Imamura, Yoshinori; Goto, Hideaki; Suto, Hirotaka; Chayahara, Naoko; Toyoda, Masanori; Ito, Yasuhiro; Miya, Akihiro; Miyauchi, Akira; Otsuki, Naoki; Nibu, Ken‐ichi; Minami, Hironobu
• Is Part Of: Head & neck. Volume 41:Issue 9(2019)
• Page Start: 3023
• Page End: 3032
• Publication Date: 2019-04-23
• Subjects: high tumor burden -- lenvatinib -- multitarget kinase inhibitors -- radioiodine‐refractory differentiated thyroid cancer -- tumor growth parameters; Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.25784
• Languages: English
• ISSNs: 1043-3074

Abstract

Abstract: Background: Multitarget kinase inhibitors (m‐TKI), including lenvatinib, are now available as treatment options for radioiodine‐refractory differentiated thyroid cancer (RR‐DTC). However, the optimal timing of treatment initiation with m‐TKI in these patients remains to be defined. Methods: We retrospectively reviewed the clinical records of 30 consecutive patients with RR‐DTC. The relationship between clinical characteristics was evaluated, including tumor growth parameters at pretreatment/post‐treatment and efficacy of lenvatinib. Results: A total of 26 patients with RR‐DTC treated with lenvatinib were evaluable for response and eligible for analysis. From the results of multivariate analysis, baseline tumor size and tumor‐related symptoms were independent negative prognostic factors for overall survival (OS) and progression‐free survival (PFS). Pretreatment tumor growth parameters were not prognostic for either PFS or OS. Conclusions: Patients with RR‐DTC with a high tumor burden and tumor‐related symptoms had significantly worse prognosis. Greater tumor reduction after starting lenvatinib may lead to better prognosis, irrespective of pretreatment high tumor growth rate.